Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Sickle Cell Anemia (HbSS): later-stage trial registry

1 of 1 indexed Sickle Cell Anemia (HbSS) trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Sickle Cell Anemia (HbSS): 1 US clinical trial tracked, 1 recruiting.

Sickle Cell Anemia (HbSS) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 1 of these trials.

Enrollment posture brief

Registry condition sickle-cell-anemia-hbss

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Sickle Cell Anemia (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Sickle Cell Anemia (HbSS)

Sickle Cell Anemia (HbSS) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sickle Cell Anemia (HbSS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sickle Cell Anemia (HbSS) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Sickle Cell Anemia (HbSS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PK-optimized oral hydroxyurea at MTD until 15 years of age. Drug
1 trials

US sites by state

Facility locations filed on Sickle Cell Anemia (HbSS) trials. A trial with sites in several states counts in each.

Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sickle Cell Anemia (HbSS) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Anemia (HbSS) condition card totals 1 registered trials; most-linked intervention PK-optimized oral hydroxyurea at MTD until 15 years of age.; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.